Adverum Biotechnologies, Inc. (ADVM) Financials
ADVM Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 173.0 million | 89.5 million |
2023-09-30 | 196.8 million | 94.1 million |
2023-06-30 | 241.4 million | 110.3 million |
2023-03-31 | 275.6 million | 117.8 million |
ADVM Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -21.5 million | 4.1 million |
2023-09-30 | -24.4 million | 4.4 million |
2023-06-30 | -23.3 million | 4.5 million |
2023-03-31 | -22.5 million | 4.6 million |
ADVM Net Income
No data available :(
ADVM Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | - | - | 75.0 million |
2023-09-30 | 117.1 million | - | 75.5 million |
2023-06-30 | 141.5 million | - | 91.2 million |
2023-03-31 | 164.3 million | - | 97.6 million |
ADVM Shares Outstanding
ADVM Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 192000 | 15.3 million | 10.9 million | - |
2023-09-30 | 495000 | 20.7 million | 13.8 million | - |
2023-06-30 | 36000 | 20.6 million | 12.5 million | - |
2023-03-31 | 85000 | 21.1 million | 12.8 million | - |
ADVM Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | - |
2023-09-30 | - | 1.5 million |
2023-06-30 | - | 7.0 million |
2023-03-31 | 3.6 million | 3.0 million |
ADVM
Price: $10
52 week price:
Earnings Per Share: -11.60 USD
P/E Ratio: -1.37
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 198800
Ebitda: -14.0 millionMarket Capitalization: 248.5 million